These findings are significant in the context of HL since (i) IL-8, which can have implications for HL progression, is among the significantly upregulated genes listed in our series; (ii) NF-kB signaling is known to be a crucial factor in HL pathogenesis; and iii) silencing IL17RB expression with siRNA has been shown to enhance the anticancer activity of doxorubicin, potentially enhancing the efficacy of existing treatments [31]. The gene discussed is CXCL8; the disease is Hodgkins lymphoma.